Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;16(3):8-20.
doi: 10.3747/co.v16i3.377.

Optimal use of taxanes in metastatic breast cancer

K M King  1 , S Lupichuk, L Baig, M Webster, S Basi, D Whyte, S Rix
Affiliations

Optimal use of taxanes in metastatic breast cancer

K M King et al. Curr Oncol. 2009 May.

Abstract

The role of taxanes in the treatment of breast cancer is becoming increasingly important. In clinical practice, the taxanes are now standard therapy in both early-stage and metastatic breast cancer. Since the 1990s, multiple randomized clinical trials have been evaluating the efficacy of taxanes in the treatment of metastatic breast cancer. These trials have included treatment with taxanes alone or in combination with other chemotherapeutic agents. Pre-existing published guidelines for the use of taxanes in the management of metastatic breast cancer are available. The mandate of the Alberta Cancer Board Provincial Breast Tumour Group Guideline Panel was to consider and adapt the recommendations of the existing guidelines and to develop de novo guidelines to account for current evidence. For this task, the panel used the ADAPTE process, which is a systematic process of guideline adaptation developed by the ADAPTE Collaboration.The recommendations formulated by the panel included the identification of taxane regimens that could be offered in anthracycline-naïve patients, anthracycline-pretreated or -resistant patients, and patients overexpressing the human epidermal growth factor receptor 2. Potential toxicities and benefits in terms of time to progression, progression-free survival, overall survival, and quality of life were also considered.

Keywords: Metastatic breast cancer; chemotherapy; docetaxel; nab-paclitaxel; paclitaxel.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Single-agent taxane compared with non-taxane/non-anthracycline: meta-analysis of overall survival – ci = confidence interval.
FIGURE 2
FIGURE 2
Single-agent taxane compared with non-taxane/non-anthracycline: meta-analysis of overall response –. ci = confidence interval.
FIGURE 3
FIGURE 3
Taxane/non-anthracycline regimen compared with single-agent taxane: meta-analysis of overall response ,,. ci = confidence interval.
See this image and copyright information in PMC

References

    1. Canadian Cancer Society and the National Cancer Institute of Canada . Canadian Cancer Statistics 2007. Toronto: Canadian Cancer Society; 2007.
    1. Ries LAG, Melbert D, Krapcho M, et al., editors. Bethesda, MD: National Cancer Institute; 2007. seer Cancer Statistics Review 1975–2004 [Web resource] (based on November 2006 seer data submission). [Available online at: seer.cancer.gov/csr/1975_2004/; cited January 2007]
    1. The adapte Collaboration Manual for Guideline Adaptation. Ver. 1.0. The adapte Collaboration; n.d. [Available online at: www.adapte.org; registration required]
    1. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol. 1995;13:502–12. - PubMed
    1. Elit L, Zitzelsberger L, Fung-Kee-Fung M, et al. Use of systemic therapy in women with recurrent ovarian cancer—development of a national clinical practice guideline. Gynecol Oncol. 2007;106:181–92. - PubMed